Cargando…
Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow
BACKGROUND: The purpose was to evaluate the dosimetric effects in prostate cancer treatment caused by anatomical changes occurring during the time frame of adaptive replanning in a magnetic resonance linear accelerator (MR-linac) workflow. METHODS: Two MR images (MR1 and MR2) were acquired with 30 m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350593/ https://www.ncbi.nlm.nih.gov/pubmed/32650811 http://dx.doi.org/10.1186/s13014-020-01604-5 |
_version_ | 1783557299017613312 |
---|---|
author | Mannerberg, Annika Persson, Emilia Jonsson, Joakim Gustafsson, Christian Jamtheim Gunnlaugsson, Adalsteinn Olsson, Lars E. Ceberg, Sofie |
author_facet | Mannerberg, Annika Persson, Emilia Jonsson, Joakim Gustafsson, Christian Jamtheim Gunnlaugsson, Adalsteinn Olsson, Lars E. Ceberg, Sofie |
author_sort | Mannerberg, Annika |
collection | PubMed |
description | BACKGROUND: The purpose was to evaluate the dosimetric effects in prostate cancer treatment caused by anatomical changes occurring during the time frame of adaptive replanning in a magnetic resonance linear accelerator (MR-linac) workflow. METHODS: Two MR images (MR1 and MR2) were acquired with 30 min apart for each of the 35 patients enrolled in this study. The clinical target volume (CTV) and organs at risk (OARs) were delineated based on MR1. Using a synthetic CT (sCT), ultra-hypofractionated VMAT treatment plans were created for MR1, with three different planning target volume (PTV) margins of 7 mm, 5 mm and 3 mm. The three treatment plans of MR1, were recalculated onto MR2 using its corresponding sCT. The dose distribution of MR2 represented delivered dose to the patient after 30 min of adaptive replanning, omitting motion correction before beam on. MR2 was registered to MR1, using deformable registration. Using the inverse deformation, the structures of MR1 was deformed to fit MR2 and anatomical changes were quantified. For dose distribution comparison the dose distribution of MR2 was warped to the geometry MR1. RESULTS: The mean center of mass vector offset for the CTV was 1.92 mm [0.13 – 9.79 mm]. Bladder volume increase ranged from 12.4 to 133.0% and rectum volume difference varied between −10.9 and 38.8%. Using the conventional 7 mm planning target volume (PTV) margin the dose reduction to the CTV was 1.1%. Corresponding values for 5 mm and 3 mm PTV margin were 2.0% and 4.2% respectively. The dose to the PTV and OARs also decreased from D1 to D2, for all PTV margins evaluated. Statistically significant difference was found for CTV D(min) between D1 and D2 for the 3 mm PTV margin (p < 0.01). CONCLUSIONS: A target underdosage caused by anatomical changes occurring during the reported time frame for adaptive replanning MR-linac workflows was found. Volume changes in both bladder and rectum caused large prostate displacements. This indicates the importance of thorough position verification before treatment delivery and that the workflow needs to speed up before introducing margin reduction. |
format | Online Article Text |
id | pubmed-7350593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73505932020-07-14 Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow Mannerberg, Annika Persson, Emilia Jonsson, Joakim Gustafsson, Christian Jamtheim Gunnlaugsson, Adalsteinn Olsson, Lars E. Ceberg, Sofie Radiat Oncol Research BACKGROUND: The purpose was to evaluate the dosimetric effects in prostate cancer treatment caused by anatomical changes occurring during the time frame of adaptive replanning in a magnetic resonance linear accelerator (MR-linac) workflow. METHODS: Two MR images (MR1 and MR2) were acquired with 30 min apart for each of the 35 patients enrolled in this study. The clinical target volume (CTV) and organs at risk (OARs) were delineated based on MR1. Using a synthetic CT (sCT), ultra-hypofractionated VMAT treatment plans were created for MR1, with three different planning target volume (PTV) margins of 7 mm, 5 mm and 3 mm. The three treatment plans of MR1, were recalculated onto MR2 using its corresponding sCT. The dose distribution of MR2 represented delivered dose to the patient after 30 min of adaptive replanning, omitting motion correction before beam on. MR2 was registered to MR1, using deformable registration. Using the inverse deformation, the structures of MR1 was deformed to fit MR2 and anatomical changes were quantified. For dose distribution comparison the dose distribution of MR2 was warped to the geometry MR1. RESULTS: The mean center of mass vector offset for the CTV was 1.92 mm [0.13 – 9.79 mm]. Bladder volume increase ranged from 12.4 to 133.0% and rectum volume difference varied between −10.9 and 38.8%. Using the conventional 7 mm planning target volume (PTV) margin the dose reduction to the CTV was 1.1%. Corresponding values for 5 mm and 3 mm PTV margin were 2.0% and 4.2% respectively. The dose to the PTV and OARs also decreased from D1 to D2, for all PTV margins evaluated. Statistically significant difference was found for CTV D(min) between D1 and D2 for the 3 mm PTV margin (p < 0.01). CONCLUSIONS: A target underdosage caused by anatomical changes occurring during the reported time frame for adaptive replanning MR-linac workflows was found. Volume changes in both bladder and rectum caused large prostate displacements. This indicates the importance of thorough position verification before treatment delivery and that the workflow needs to speed up before introducing margin reduction. BioMed Central 2020-07-10 /pmc/articles/PMC7350593/ /pubmed/32650811 http://dx.doi.org/10.1186/s13014-020-01604-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mannerberg, Annika Persson, Emilia Jonsson, Joakim Gustafsson, Christian Jamtheim Gunnlaugsson, Adalsteinn Olsson, Lars E. Ceberg, Sofie Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title | Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title_full | Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title_fullStr | Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title_full_unstemmed | Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title_short | Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow |
title_sort | dosimetric effects of adaptive prostate cancer radiotherapy in an mr-linac workflow |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350593/ https://www.ncbi.nlm.nih.gov/pubmed/32650811 http://dx.doi.org/10.1186/s13014-020-01604-5 |
work_keys_str_mv | AT mannerbergannika dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT perssonemilia dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT jonssonjoakim dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT gustafssonchristianjamtheim dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT gunnlaugssonadalsteinn dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT olssonlarse dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow AT cebergsofie dosimetriceffectsofadaptiveprostatecancerradiotherapyinanmrlinacworkflow |